Med-IQ
E-Publication E-Publication

Advances in Familial Hypercholesterolemia Identification and Management: Clinical Concepts and Expert Insights


Time to Complete:
1 Hour
Released:
12/4/12
Expires:
12/3/13

Maximum Credits:

1.0 AMA PRA Category 1 Credit(s)

E-Publication E-Publication
Time to Complete:
1 Hour

Released:
12/4/12

Expires:
12/3/13

Maximum Credits:
1.0 AMA PRA Category 1 Credit(s)
Share on:
E-Publication E-Publication

Share on:


Time to Complete:
1 Hour
Released:
12/4/12
Expires:
12/3/13


Maximum Credits:
1.0 AMA PRA Category 1 Credit(s)


Overview: This interactive CME initiative explores strategies for recognizing the risk of familial hypercholesterolemia (FH) and accurately diagnosing the disease based on contemporary clinical practice guidelines. The activity also includes a discussion of current evidence- and guideline-based treatment strategies, as well as an in-depth look at evolving management strategies. Integrated audio segments are also included to highlight expert faculty perspectives regarding the role of cascade screening, the relationship between genetics and treatment in FH, and the potential application of new and emerging therapies.

Faculty

Peter P. Toth, MD, PhD

Director of Preventive Cardiology

CGH Medical Center

Sterling, IL

Professor of Clinical Family and Community Medicine

University of Illinois College of Medicine

Peoria, IL

Professor of Clinical Medicine

Michigan State University College of Osteopathic Medicine

East Lansing, MI

James Underberg, MD, MS, FACPM, FACP, FASH, FNLA

Lipidology & Cardiovascular Disease Prevention

Clinical Assistant Professor of Medicine

NYU Medical School & NYU Center for CV Prevention

Director, Bellevue Hospital Lipid Clinic

Bellevue Hospital

New York, NY


Disclosure Policy

Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.


Disclosure Statement

The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.  

Peter P. Toth, MD, PhD
Consulting fees/advisory boards: Amgen, Genzyme, Kowa Pharmaceuticals America, Inc., Merck & Co., Inc., Regeneron
Fees received for promotional/non-CME activities: Abbott Laboratories, Amylin Pharmaceuticals, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Kowa Pharmaceuticals America, Inc., Merck & Co., Inc.
 
James Underberg, MS, MD
Consulting fees/advisory boards: Aegerion Pharmaceuticals, Inc., Amarin Corp., Genzyme, Liposcience Inc., Sanofi-aventis U.S. Inc.,
Fees received for promotional/non-CME activities: Abbott Laboratories, Daiichi Sankyo, Co. Ltd.,  Eli Lilly and Company, Forest Laboratories, Inc., GlaxoSmithKline, Kowa Pharmaceuticals America, Inc., Liposcience Inc., Merck & Co., Inc.


The activity planners and peer reviewers have no financial relationships to disclose.


This activity has been approved for AMA PRA Category 1 Credit™.


This activity is supported by an educational grant from Genzyme, a Sanofi Company.

Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.

The following material has been developed to accompany this activity:

E-brief Issue #1: Therapeutic Lifestyle Modifications for Managing Familial Hypercholesterolemia

E-brief Issue #2: New Treatment Options for Homozygous Familial Hypercholesterolemia

Note: This material is not accredited for CME and, therefore, does not offer any CME/CE credit.

Need help? If you need to speak with a member of our team, please call (toll-free) 866 858 7434 or e-mail info@med-iq.com. For technical assistance, please refer to our support manual.